Ruth Riisnaes - Dissemin

All papers authored by Ruth Riisnaes

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2023 Alistair Ring

, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Table S5 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Figure S3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Figure 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Figure 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Table S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Figure 3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Data from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Figure S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Figure S1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Table S2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Table 2 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring

, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Table S4 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring

, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Supplementary Table S3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Figure 4 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Alistair Ring, Lucy S. Kilburn, Alex Pearson, Laura Moretti, Angelica Afshari-Mehr

, Andrew M. Wardley, Bora Gurel, Iain R. Macpherson, Ruth Riisnaes

, Richard D. Baird, Sue Martin, Rebecca Roylance, Hannah Johnson, Ana Ferreira, Matthew C. Winter and 9 other authors

Table 1 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

This paper was not found in any repository, but could be made available legally by the author.

Alistair Ring

, Lucy S. Kilburn

, Alex Pearson

, Laura Moretti

, Angelica Afshari-Mehr

, Andrew M. Wardley

, Bora Gurel

, Iain R. Macpherson

, Ruth Riisnaes

, Richard D. Baird

, Sue Martin

, Rebecca Roylance

, Hannah Johnson

, Ana Ferreira

, Matthew C. Winter

and 9 other authors

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Upload

Susana Banerjee

, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud

, Ruth Riisnaes

, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout and 14 other authors

Supplementary Table from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Upload

Susana Banerjee

, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud

, Ruth Riisnaes

, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout and 14 other authors

Data from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Upload

Susana Banerjee

, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud

, Ruth Riisnaes

, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout and 14 other authors

Supplementary Figure from A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Upload

2022 Marta J. Llorca-Cardenosa

, Lauren I. Aronson

, Dragomir B. Krastev

, Jadwiga Nieminuszczy

, John Alexander

, Feifei Song

, Malgorzata Dylewska

, Ronan Broderick

, Rachel Brough

, Astrid Zimmermann

, Frank T. Zenke

, Bora Gurel

, Ruth Riisnaes

, Ana Ferreira

, Theodoros Roumeliotis

and 8 other authors

SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

All papers authored by Ruth Riisnaes